Physician profile
De Tan
NPI 1851384044
$4,110.12
in general payments reported to CMS, 2019-2025
16 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $207 · 2021: $112 · 2022: $330 · 2023: $769 · 2024: $788 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.53 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $937.80 | 2019-2024 | Vemlidy, Epclusa |
| Abbvie INC. | $901.58 | 2019-2025 | |
| Genzyme Corporation | $660.60 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $366.00 | 2019-2025 | Entyvio |
| Janssen Scientific Affairs, LLC | $327.15 | 2025 | |
| Madrigal Pharmaceuticals | $269.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $140.52 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $126.93 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $122.31 | 2025 | Zymfentra |
| Janssen Biotech, INC. | $74.99 | 2024 | Stelara |
| Olympus America INC. | $53.32 | 2023-2024 | Evis Exera III Colonovideoscope, Endoclot Sis |
| Biotronik INC. | $51.90 | 2019 | |
| Exact Sciences Corporation | $23.92 | 2023 | Cologuard Collection Kit |
| Qol Medical, LLC | $22.12 | 2019 | |
| Pfizer INC. | $16.46 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw De Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.